Evan Alley, MD
Dr. Evan Alley is a medical oncologist who serves as Section Head for Thoracic Oncology at the Cleveland Clinic Florida in Weston, Florida. His clinical focus is on lung cancer, malignant pleural mesothelioma and other thoracic cancers. He is board-certified in Medical Oncology and Hematology.[1]
Dr. Alley is knowledgeable in the use of biologics, chemotherapy, and immunotherapy, as well as novel targeted treatments. Where possible, he enrolls his patients in clinical drug trials for the treatment of their conditions.[1]
In addition to lung cancer, pleural mesothelioma, and peritoneal mesothelioma, Dr. Alley specializes in treating thymic cancer, thymoma, small cell neuroendocrine carcinoma, and carcinoid tumors of the lungs.[1]
Education and Career
Dr. Alley earned his medical degree at the University of Kansas School of Medicine and then completed his internship and residency in Internal Medicine at the Sidney Kimmel Medical College at Thomas Jefferson University and Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, and remained in Philadelphia to complete his fellowship in Hematology and Medical Oncology at the University of Pennsylvania Health System.[2]
After spending several years in private practice, Dr. Alley served as the Chief of Hematology/Oncology for Penn Presbyterian Medical Center. He was also the co-director of the Penn Mesothelioma and Pleural Malignancy Program before joining the medical staff at the Cleveland Clinic Florida.
Professional Memberships and Activities
Dr. Alley is a member of several professional medical organizations, including:[2]
- American Association for Cancer Research
- American Society of Clinical Oncology
- International Association for the Study of Lung Cancer
- International Mesothelioma Interest Group
Research
In addition to his clinical care, Dr. Alley is actively involved in research and clinical trials exploring innovative approaches to treating lung cancer and malignant pleural mesothelioma. He is the author of numerous research publications and has presented his research at both national and international meetings.[2]
His publications include:[3]
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen RB, Lieberman DB, Majmundar KS, Savitch SL, Morrissette JJD, Hwang WT, Elenitoba-Johnson KSJ, Langer CJ, Carpenter EL.JAMA Oncol. 2019 Feb 1;5(2):173-180. doi: 10.1001/jamaoncol.2018.4305.PMID: 30325992 Free PMC article.
Immunotherapy and radiation therapy for malignant pleural mesothelioma. Alley EW, Katz SI, Cengel KA, Simone CB 2nd.Transl Lung Cancer Res. 2017 Apr;6(2):212-219. doi: 10.21037/tlcr.2017.04.01.PMID: 28529903 Free PMC article. Review.
Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy. Kotecha R, Tonse R, Rubens M, Appel H, Albrecht F, Kaywin P, Alley EW, Tom MC, Mehta MP.Cancers (Basel). 2021 May 2;13(9):2186. doi: 10.3390/cancers13092186.PMID: 34063225 Free PMC article. Review.
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma. Zauderer MG, Alley EW, Bendell J, Capelletto E, Bauer TM, Callies S, Szpurka AM, Kang S, Willard MD, Wacheck V, Varghese AM.Invest New Drugs. 2021 Aug;39(4):1081-1088. doi: 10.1007/s10637-021-01086-6. Epub 2021 Mar 4.PMID: 33660194 Free PMC article. Clinical Trial.
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. Aggarwal C, Haas AR, Metzger S, Aguilar LK, Aguilar-Cordova E, Manzanera AG, Gómez-Hernández G, Katz SI, Alley EW, Evans TL, Bauml JM, Cohen RB, Langer CJ, Albelda SM, Sterman DH.Mol Ther. 2018 May 2;26(5):1198-1205. doi: 10.1016/j.ymthe.2018.02.015. Epub 2018 Feb 21.PMID: 29550074 Free PMC article. Clinical Trial.
